Company News
BofA Names Argenx, Vertex Top Biotech Picks
BofA reaffirmed Argenx and Vertex as top large‑cap biotech picks for 2026 with price targets of $1,013 and $598 respectively.
Argenx’s Vvygart shows strong sales in generalized myasthenia gravis and C
